Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-50 (canceled)

51. (currently amended) A compound of the formula I(A-F) having the following structure:



IA-IF

wherein: the carbon atom designated * is in the R or S configuration;

R^1 is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl, each of which is optionally substituted with 1 to 3 substituents independently selected at each occurrence thereof from C_1-C_3 alkyl, halogen, aryl, -CN, OR^9 and $-NR^9R^{10}$;

R^2 is H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, C_4-C_7 cycloalkylalkyl or C_1-C_6 haloalkyl;

R^3 is H, $-OR^{11}$, $-S(O)_nR^{12}$, $-S(O)_nNR^{11}R^{12}$, $-C(O)R^{12}$, $-C(O)NR^{11}R^{12}$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, C_4-C_7 cycloalkylalkyl, -O(phenyl), or -O(benzyl), wherein each of -O(phenyl) and -O(benzyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy, or wherein when R^3 is a C_1-C_6 alkyl,

C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl group, then said group is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C_1-C_3 alkyl, halogen, aryl, -CN, -OR^9 and -NR^9R^{10}; provided that for compounds of formula IA, R^3 is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl, each of which is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C_1-C_3 alkyl, halogen, aryl, -CN, -OR^9 and -NR^9R^{10};

provided that for compounds of formula IB, R^3 is -O(phenyl), -O(benzyl), ~~-OC(O)R^{13}~~ or $S(O)_nR^{12}$, each of -O(phenyl) and -O(benzyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy;

R^4 is H, halogen, -$S(O)_nR^{12}$, -$S(O)NR^{11}R^{12}$, -CN, -$C(O)R^{12}$, -$C(O)NR^{11}R^{12}$, -$NR^{11}R^{12}$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, C_4-C_7 cycloalkylalkyl, -O(phenyl), -$OC(O)R^{13}$, or -O(benzyl), wherein each of -O(phenyl) and -O(benzyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy and wherein when R^4 is a C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl group, then said group is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C_1-C_3 alkyl, halogen, aryl, -CN, -OR^9 and -NR^9R^{10}; provided that for compounds of formula IC, R^4 is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl, each of which is optionally substituted; provided that for compounds of formula ID, R^4 is -O(phenyl), -O(benzyl), -$OC(O)R^{13}$, -$NR^{11}R^{12}$ or -$S(O)_nR^{12}$, each of -O(phenyl) and -O(benzyl) being optionally substituted, wherein R^3 and R^4 are not both H;

R^5, R^6 and R^7 in compounds of each of the formulae IA, IB, IC, ID, IE and IF are each independently H, halogen, -OR^{11}, -$S(O)_nR^{12}$, -CN, -$C(O)R^{12}$, -$NR^{11}R^{12}$, -$C(O)NR^{11}R^{12}$, -$NR^{11}C(O)R^{12}$, -$NR^{11}C(O)_2R^{12}$, -$NR^{11}C(O)NR^{12}R^{13}$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl, wherein when each of R^5, R^6 and R^7 is a C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl group, then said group is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C_1-C_3 alkyl, halogen, aryl, -CN, -OR^9 and -NR^9R^{10}, or R^5 and R^6 or R^6 and R^7 may together be -O-$C(R^{12})_2$-O-; provided that for compounds of formula IE at least one of R^5 or R^7 is fluoro, chloro, or methyl; or R^5 and R^6 are together

-O-C(R^{12})$_2$-O- in compounds of the formulae IE, but only where R^7 is fluoro, chloro or methyl; or R^7 and R^6 are together -O-C(R^{12})$_2$-O- in compounds of the formulae IE, but only where R^5 is fluoro, chloro or methyl;

R^8 is H or halogen, provided that for compounds of formula IF, R^8 is halogen;

R^9 and R^{10} are each independently H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_1-C_4 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_7 cycloalkylalkyl, -C(O)R^{13}, phenyl or benzyl, where phenyl or benzyl is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy; or R^9 and R^{10} are taken together with the nitrogen to which they are attached to form piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine;

R^{11} is H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_1-C_4 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_7 cycloalkylalkyl, -C(O)R^{13}, phenyl or benzyl, where R^{11} is a C_1-C_4 alkyl, phenyl or benzyl group, then said group is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy;

R^{12} is H, amino, C_1-C_4 alkyl, (C_1-C_4 alkyl)amino, C_1-C_4 haloalkyl, C_1-C_4 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_7 cycloalkylalkyl, phenyl or benzyl, where phenyl or benzyl is optionally substituted from 1 to 3 times with a substituent selected independently from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl and C_1-C_4 alkoxy; or R^{11} and R^{12} are taken together with the nitrogen to which they are attached to form piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine;

provided that only one of R^9 and R^{10} are taken together with the nitrogen to which they are attached to form piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine;

R^{13} is C_1-C_4 alkyl, C_1-C_4 haloalkyl or phenyl;

n is 0, 1, or 2, and;

aryl is phenyl which is optionally substituted 1-3 times with halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl and C_1-C_4 alkoxy, or

an oxide thereof, or a pharmaceutically acceptable salt thereof and, wherein if R^3 is –$S(O)_nR^{12}$, n cannot be 0, and wherein if R^3 is –OR^{11}, R^{11} cannot be hydrogen.

52. (previously presented) The compound of claim 51, wherein R^1 is C_1-C_3 alkyl.

53. (previously presented) The compound of claim 52, wherein R^1 is CH_3.

54. (previously presented) The compound of claim 51, wherein R^2 is H, C_1-C_4 alkyl or C_1-C_6 haloalkyl.

55. (previously presented) The compound of claim 54, wherein R^2 is H or CH_3.

56. (previously presented) The compound of claim 51, wherein R^3 is H or R^3 is C_1-C_4 alkyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl, each of which is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C_1-C_3 alkyl, halogen, aryl, -CN, -OR^9 and –NR^9R^{10} or R^3 is -O(phenyl) or –O(benzyl) optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy.

57. (previously presented) The compound of claim 56, wherein R^3 is methyl, ethyl, propyl, or isopropyl.

58. (previously presented) The compound of claim 56, wherein R^3 is -O(phenyl) or –O-CH_2-(phenyl), each of which is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy.

59. (previously presented) The compound of claim 56, wherein R^3 is H.

60. (previously presented) The compound of claim 51, wherein R^4 is H, or R^4 is –$NR^{11}R^{12}$ or R^4 is C_1-C_4 alkyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl, each of which is optionally substituted, or wherein R^4 is -O(phenyl) or -O(benzyl), each of which is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy.

61. (previously presented) The compound of claim 60, wherein R^4 is methyl, ethyl, propyl, or isopropyl.

62. (previously presented) The compound of claim 60, wherein R^4 is -O(phenyl) or $-O(CH_2)$(phenyl), each of which is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy.

63. (previously presented) The compound of claim 60, wherein R^4 is H.

64. (previously presented) The compound of claim 51, wherein R^4 is halogen.

65. (previously presented) The compound of claim 51, wherein one of R^3 and R^4 is H and the other is CH_3.

66. (previously presented) The compound of claim 51, wherein R^5, R^6 and R^7 are each H, halogen, $-OR^{11}$, $-NR^{11}R^{12}$, C_1-C_6 alkyl and substituted C_1-C_6 alkyl.

67. (previously presented) The compound of claim 66, wherein R^5, R^6 and R^7 are each H.

68. (previously presented) The compound of claim 66, wherein one of R^5 or R^7 is F, Cl, or Me and the other of R^5 or R^7 and R^6 are H, halogen, $-OR^{11}$, $-NR^{11}R^{12}$, or optionally substituted C_1-C_6 alkyl.

69. (previously presented) The compound of claim 68, wherein R^5 is F, Cl or Me; and R^7 is H.

70. (previously presented) The compound of claim 68, wherein R^5 is F, Cl or Me; and R^6 is H.

71. (previously presented) The compound of claim 51, wherein R^8 is halogen.

72. (previously presented) The compound of claim 71, wherein R^8 is fluoro.

73. (currently amended) The compound of claim 51, wherein:

R^1 is C_1-C_3 alkyl;

R^2 is H, C_1-C_4 alkyl or C_1-C_6 haloalkyl;

R^3 is C_1-C_4 alkyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl, each of which is optionally substituted, or R^3 is –O(phenyl) or –O(benzyl), each of which is optionally substituted, or R^3 is H;

R^4 is H, C_1-C_4 alkyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl, each of which, other than H, is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C_1-C_3 alkyl, halogen, aryl, -CN, -OR^9 and –NR^9R^{10}, or R^4 is -$NR^{11}R^{12}$, -O(phenyl) or –O(benzyl), wherein said –O(phenyl) or –O(benzyl), is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy;

or R^4 is halogen;

R^5, R^6 and R^7 are each halogen, -OR^{11}, -$NR^{11}R^{12}$, or C_1-C_6 alkyl, or one of R^5 and R^7 is Cl, F or Me and the other of R^5 and R^7 and R^6 is H, halogen, -$NR^{11}R^{12}$, C_1-C_6 alkyl or substituted C_1-C_6 alkyl.

74. (previously presented) The compound of claim 51, wherein:

R^1 is CH_3;

R^2 is H or CH_3;

R^3 is H, methyl, ethyl, propyl, isopropyl, -O(phenyl) or -O-CH_2-(phenyl), wherein said –O(phenyl) or –O-CH_2-(phenyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy;

R^4 is H, F, methyl, ethyl, propyl, isopropyl, –O(phenyl) or –O-CH_2-(phenyl), wherein said -O(phenyl) or –O-CH_2-(phenyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy;

R^5, R^6 and R^7 are each H or R^5 is F, Cl or Me, or one of R^6 or R^7 is H and the other of R^6 and R^7 is halogen, -OR^{11}, -$NR^{11}R^{12}$, or optionally substituted C_1-C_6 alkyl.

75. (previously presented) The compound of claim 73, wherein R^8 is halogen.

76. (previously presented) The compound according to claim 51, wherein the carbon atom designated * is in the R configuration.

77. (previously presented) The compound according to claim 51, wherein the carbon atom designated * is in the S configuration.

78. (previously presented) A composition comprising a mixture of stereoisomeric compounds of claim 51 wherein the carbon atom designated * is in the S or R configuration.

79. (previously presented) The compound according to claim 51, selected from the group consisting of the following compounds:

4-(4-methoxy)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

2,7-dimethyl-4-(4-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;

2,7-dimethyl-4-(3-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,4-difluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

2,7-dimethyl-4-(4-fluoro-3-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(3-chloro-4-fluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(3-chloro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

2,7-dimethyl-4-(4-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;

2,7-dimethyl-4-(3-fluoro-4-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(4-chloro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(4-chloro-3-fluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,4-dichloro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

7-ethyl-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,4-difluoro)phenyl-7-ethyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;

7-fluoro-4-(3-fluoro-4-methoxy)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;

7-fluoro-4-(3-fluoro-4-methyl)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;

7-fluoro-4-(4-chloro-3-fluoro)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,4-difluoro)phenyl-7-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinoline;

4-(3-chloro)phenyl-7-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinoline;

2-methyl-4-phenyl-7-trifluoromethyl-1,2,3,4-tetrahydroisoquinoline;

4-phenyl-1,2,7-trimethyl-1,2,3,4-tetrahydroisoquinoline;

2,8-dimethyl-7-fluoro-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

2-methyl-7-phenoxy-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

7-(4-methoxy)phenoxy-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

7-benzyloxy-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

2,8-dimethyl-4-(4-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,4-difluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,5-difluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;

2,8-dimethyl-4-(3-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;

2,8-dimethyl-4-(4-fluoro-3-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(3-chloro-4-fluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,4-dichloro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(3-chloro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(4-chloro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(4-chloro-3-fluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;

2,8-dimethyl-4-(4-methoxy)phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(4-cyano)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;

2,8-dimethyl-4-(4-trifluoromethyl)phenyl-1,2,3,4-tetrahydroisoquinoline;

2,8-dimethyl-4-(4-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;

2-methyl-8-(N-methylamino)methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

8-(hydroxy)methyl-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

2-methyl-4-phenyl-8-sulfonamide-1,2,3,4-tetrahydroisoquinoline;

2-methyl-8-(N-methyl)sulfonamide-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,5-difluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(3-chloro-5-fluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,5-difluoro)phenyl-1,2,7-trimethyl-1,2,3,4-tetrahydroisoquinoline;

2-methyl-4-phenyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-N-methylmethanamine;

N-methyl(2-methyl-4-phenyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-N-methylmethanamine;

(2-methyl-4-phenyl-1,2,3,4-tetrahydro-7-isoquinolinyl)methanol; and

an oxide thereof, or a pharmaceutically acceptable salt thereof.

80. (previously presented) The compound according to claim 51, selected from the group consisting of the following compounds:

R^1	R^2	R^3	R^4	R^5	R^6	R^7	R^8
Me	H	H	Me	H	OMe	H	H
Me	H	H	Me	H	F	H	H
Me	H	H	Me	F	H	H	H
Me	H	H	Me	F	F	H	H
Me	H	H	Me	Me	F	H	H
Me	H	H	Me	Cl	F	H	H
Me	H	H	Me	Cl	H	H	H
Me	H	H	Me	H	Me	H	H
Me	H	H	Me	F	Me	H	H
Me	H	H	Me	H	Cl	H	H
Me	H	H	Me	F	Cl	H	H
Me	H	H	Me	Cl	Cl	H	H
Me	H	H	Et	H	H	H	H
Me	H	H	Et	F	F	H	H
Me	H	H	F	F	OMe	H	H
Me	H	H	F	F	Me	H	H
Me	H	H	F	F	Cl	H	H
Me	H	H	F	F	F	H	H
Me	H	H	F	Cl	H	H	H
Me	H	H	CF_3	H	H	H	H
Me	Me	H	Me	H	H	H	H
Me	H	Me	Me	H	H	H	H
Me	H	Me	F	H	H	H	H
Me	H	H	O(Ph)	H	H	H	H
Me	H	H	O(4-OMePh)	H	H	H	H
Me	H	H	$O(CH_2Ph)$	H	H	H	H
Me	H	Me	H	H	F	H	H
Me	H	Me	H	F	F	H	H
Me	H	Me	H	F	H	F	H
Me	H	Me	H	F	H	H	H
Me	H	Me	H	Me	F	H	H
Me	H	Me	H	Cl	F	H	H

R^1	R^2	R^3	R^4	R^5	R^6	R^7	R^8
Me	H	Me	H	Cl	Cl	H	H
Me	H	Me	H	Cl	H	H	H
Me	H	Me	H	H	Cl	H	H
Me	H	Me	H	F	Cl	H	H
Me	H	Me	H	H	OMe	H	H
Me	H	Me	H	H	CN	H	H
Me	H	Me	H	H	CF_3	H	H
Me	H	Me	H	H	Me	H	H
Me	H	CH_2NHMe	H	H	H	H	H
Me	H	CH_2OH	H	H	H	H	H
Me	H	SO_2NH_2	H	H	H	H	H
Me	H	SO_2NHMe	H	H	H	H	H
Me	H	H	Me	F	H	F	H
Me	H	H	Me	F	H	Cl	H
Me	Me	H	Me	F	H	F	H
Me	H	H	Me	F	F	F	H
Et	H	H	Me	H	F	H	H
Me	H	H	CH_2NH_2	H	H	H	H
Me	H	H	CH_2NHMe	H	H	H	H
Me	H	H	CH_2OH	H	H	H	H.

81. (previously presented) The compound according to claim 51, wherein, the compound has the formula:



, where:

R^4	R^5	R^6	R^7
Me	H	F	F
Me	F	H	F
Me	H	F	H
Me	H	H	F.

82. (previously presented) The compound according to claim 79, which is the (+) stereoisomer.

83. (previously presented) The compound according to claim 79, which is the (-) stereoisomer.

84. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 51.

85. (previously presented) A method of treating a disorder selected from the group consisting of attention deficit disorder, hyperactivity disorder, anxiety, depression, post-traumatic stress disorder, supranuclear palsy, eating disorders, obsessive compulsive disorder, analgesia, nicotine addiction, panic attacks, Parkinsonism and phobia, obesity, late luteal phase syndrome or narcolepsy, cocaine addiction, amphetamine addiction, rejection sensitivity, and lack of mental or physical energy, wherein said method comprises:

administering to a patient in need of such treatment a therapeutically effective amount of a compound according to claim 51, or a pharmaceutically acceptable salt thereof.

86-89. (canceled)

90. (previously presented) The method of claim 85 wherein the (+)-stereoisomer of the compound is employed.

91. (previously presented) The method of claim 85, wherein the (-)-stereoisomer of the compound is employed.

92. (previously presented) The method of claim 85, wherein the disorder is attention deficit disorder or hyperactivity disorder.

93. (canceled)